Kiadis Pharma Announces Today Five-Year Follow-Up Of Patients With High-Risk Malignancies From Its Phase I/II

Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™ and Study Meets Primary Objective.ATIR™ is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for patients who do not have a standard of care stem cell donor available.

Link:
www.prnewswire.com/news-releases/kiadis-pharma-completes-five-year-follow-up-of-its-phase-iii-clinical-study-with-blood-cancer-product-atir-and-study-meets-primary-objective-223246751.html